Inferior vena cava filters in the management of cancer-associated venous thromboembolism: A systematic review

Oncology Reviews

Volumn 4, Issue 3, 2010, Pages 147-157

  Raman, Rachna ^a   Leming, Philip D ^a   Bhandari, Manish ^a   Long, Daniel ^a   Streiff, Michael B ^b  

^a CHRIST HOSPITAL   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cancer; IVC filter; Review; Thromboembolism

Indexed keywords

EID: 84879607306     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-010-0042-3     Document Type: Review

References (81)

1. Lyman GH et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25(34):5490-5505.
2. Silverstein MD et al (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 158(6):585-593.
3. Heit JA et al (2000) Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160(6):809-815.
4. Barritt DW, Jordan SC (1960) Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1(7138):1309-1312.
5. Alpert JS, Dalen JE (1994) Epidemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 36(6):417-422.
6. Horlander KT, Mannino DM, Leeper KV (2003) Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 163(14):1711-1717.
7. Goldhaber SZ, Visani L, De Rosa M (1999) Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 353(9162): 1386-1389.
8. Palareti G et al (2002) Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 87(1):7-12.
9. Hutten BA et al (2000) Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 18(17):3078-3083.
10. Levine MN et al (1998) Hemorrhagic complications of anticoagulant treatment. Chest 114(5 Suppl):511S-523S.
11. Prandoni P et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484-3488.
12. Stein PD, Kayali F, Olson RE (2004) Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 164(14):1541-1545.
13. Seddighzadeh A, Shetty R, Goldhaber SZ (2007) Venous thromboembolism in patients with active cancer. Thromb Haemost 98(3):656-661.
14. Athanasoulis CA et al (2000) Inferior vena caval filters: review of a 26-year single-center clinical experience. Radiology 216(1):54-66.
15. Arnold TE et al (1993) Potential of overuse of the inferior vena cava filter. Surg Gynecol Obstet 177(5):463-467.
16. Jarrett BP, Dougherty MJ, Calligaro KD (2002) Inferior vena cava filters in malignant disease. J Vasc Surg 36(4):704-707.
17. Levin JM et al (1993) Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 43(6):1111-1114.
18. Olin JW et al (1987) Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med 147(12):2177-2179.
19. Walsh DB et al (1987) Metastatic cancer. A relative contraindication to vena cava filter placement. Cancer 59(1):161-163.
20. Schiff D, DeAngelis LM (1994) Therapy of venous thromboembolism in patients with brain metastases. Cancer 73(2):493- 498.
21. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692-694.
22. Schleich JM et al (2001) Long-term follow-up of percutaneous vena cava filters: A prospective study in 100 consecutive patients. Eur J Vasc Endovasc Surg 21(5):450-457.
23. Barginear MF et al (2009) Need for inferior vena cava filters in cancer patients: A surrogate marker for poor outcome. Clin Appl Thromb Hemost 15(3):263-269.
24. Calligaro KD et al (1991) Thromboembolic complications in patients with advanced cancer: anticoagulation versus Greenfield filter placement. Ann Vasc Surg 5(2):186-189.
25. Greenfield LJ, Proctor MC, Saluja A (1997) Clinical results of Greenfield filter use in patients with cancer. Cardiovasc Surg 5(2):145-149.
26. Ihnat DM et al (1998) Treatment of patients with venous thromboembolism and malignant disease: should vena cava filter placement be routine? J Vasc Surg 28(5):800-807.
27. Lossef SV, Barth KH (1995) Outcome of patients with advanced neoplastic disease receiving vena caval filters. J Vasc Interv Radiol 6(2):273-277.
28. Magnant JG et al (1992) Current use of inferior vena cava filters. J Vasc Surg 16(5):701-706.
29. Rosen MP, Porter DH, Kim D (1994) Reassessment of vena caval filter use in patients with cancer. J Vasc Interv Radiol 5(3):501- 506.
30. Schunn C et al (2006) Inferior vena cava filter placement in latestage cancer. Vasc Endovascular Surg 40(4):287-294.
31. Schwarz RE et al (1996) Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 14(2):652-657.
32. Wallace MJ et al (2004) Use of inferior vena caval filters and survival in patients with malignancy. Cancer 101(8):1902-1907.
33. Cohen JR, Grella L, Citron M (1992) Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer 70(7):1993- 1996.
34. Cohen JR, Tenenbaum N, Citron M (1991) Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery 109(1):12-15.
35. Feezor RJ et al (2002) Duodenal perforation with an inferior vena cava filter: an unusual cause of abdominal pain. J Vasc Surg 35(5):1010-1012.
36. Streiff MB (2000) Vena caval filters: A comprehensive review. Blood 95(12):3669-3677.
37. Greenfield LJ, Rutherford RB (1999) Recommended reporting standards for vena caval filter placement and patient follow-up. Vena Caval Filter Consensus Conference. J Vasc Interv Radiol 10(8):1013-1019.
38. Kahn SR (2006) The post-thrombotic syndrome: progress and pitfalls. Br J Haematol 134(4):357-365.
39. Kinney TB (2003) Update on inferior vena cava filters. J Vasc Interv Radiol 14(4):425-440.
40. Kahn SR (2009) Post-thrombotic syndrome after deep venous thrombosis: risk factors, prevention, and therapeutic options. Clin Adv Hematol Oncol 7(7):433-435.
41. Lee AY, Levine MN (2003) Venous thromboembolism and cancer: risks and outcomes. Circulation 107(23 Suppl 1):I17-I21.
42. Lee AY (2005) Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices. Dis Mon 51(2-3):150-157.
43. Khorana AA et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5(3):632-634.
44. Sorensen HT et al (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846-1850.
45. Chew HK et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458-464.
46. Altinbas M et al (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2(8):1266- 1271.
47. Klerk CP et al (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23(10):2130-2135.
48. Lee AY et al (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23(10):2123-2129.
49. Kakkar AK et al (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22(10):1944-1948.
50. Kearon C et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(6 Suppl):454S-545S.
51. Wagman LD et al (2008) Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 6(8):716-753.
52. Gitter MJ et al (1995) Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 70(8):725-733.
53. Krauth D et al (1987) Safety and efficacy of long-term oral anticoagulation in cancer patients. Cancer 59(5):983-985.
54. Moore FD Jr et al (1981) Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 116(4):405-407.
55. Bates SM et al (2001) Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 161(3):385-391.
56. Decousus H et al (1998) A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338(7):409-415.
57. (2005) Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112(3):416-22.
58. Billett HH et al (2007) Efficacy of inferior vena cava filters in anticoagulated patients. J Thromb Haemost 5(9):1848-1853.
59. Lee AY et al (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349(2):146-153.
60. Rodas RA et al (1998) Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: A preliminary report. J Neurosurg 89(2):200-205.
61. Goldschmidt N et al (2003) High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 98(6):1239-1242.
62. Hylek EM, Singer DE (1994) Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120(11):897-902.
63. Sjoblom L et al (2001) Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: A Swedish multicenter study. Stroke 32(11):2567-2574.
64. Gerber DE, Grossman SA, Streiff MB (2006) Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 24(8):1310-1318.
65. Weisberg LA (1985) Hemorrhagic metastatic intracranial neoplasms: clinical-computed tomographic correlations. Comput Radiol 9(2):105-114.
66. Vaughan HG Jr, Howard RG (1962) Intracranial hemorrhage due to metastatic chorionepithelioma. Neurology 12:771-777.
67. Wakai S et al (1982) Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance. Neurosurgery 10(4):437-444.
68. Kakkar AK, Levine MN (2004) Thrombosis and cancer: implications beyond Trousseau. J Thromb Haemost 2(8):1261-1262.
69. McCowan TC et al (1990) Amplatz vena caval filter: clinical experience in 30 patients. AJR Am J Roentgenol 155(1):177-181.
70. Asch MR (2002) Initial experience in humans with a new retrievable inferior vena cava filter. Radiology 225(3):835-844.
71. Lorch H et al (2000) Current practice of temporary vena cava filter insertion: A multicenter registry. J Vasc Interv Radiol 11(1):83-88.
72. Ray CE Jr (2006) Outcomes with retrievable inferior vena cava filters: A multicenter study. J Vasc Interv Radiol 17(10):1595- 1604.
73. Binkert CA, Sasadeusz K, Stavropoulos SW (2006) Retrievability of the recovery vena cava filter after dwell times longer than 180 days. J Vasc Interv Radiol 17(2 Pt 1):299-302.
74. Imberti D et al (2005) Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. J Thromb Haemost 3(7):1370-1375.
75. Millward SF et al (2001) Gunther Tulip retrievable vena cava filter: results from the Registry of the Canadian Interventional Radiology Association. J Vasc Interv Radiol 12(9):1053-1058.
76. Stefanidis D et al (2006) Extended interval for retrieval of vena cava filters is safe and may maximize protection against pulmonary embolism. Am J Surg 192(6):789-794.
77. Nazzal M, Abbas J, Shattu J (2008) Complications secondary to the Bard retrievable filter: A case report. Ann Vasc Surg 22(5):684-687.
78. Kim HS et al (2008) A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol 19(3):393-399.
79. Dovrish Z et al (2006) Retrospective analysis of the use of inferior vena cava filters in routine hospital practice. Postgrad Med J 82(964):150-153.
80. Kaufman JA et al (2006) Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. Surg Obes Relat Dis 2(2):200-212.
81. Keeling AN, Kinney TB, Lee MJ (2008) Optional inferior vena caval filters: where are we now? Eur Radiol 18(8):1556-1568.